<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016146</url>
  </required_header>
  <id_info>
    <org_study_id>99-062</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-99062</secondary_id>
    <secondary_id>NCI-G01-1941</secondary_id>
    <nct_id>NCT00016146</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Biological therapies use different ways to stimulate the immune system and stop cancer cells&#xD;
      from growing. Combining vaccine therapy with biological therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness in combining vaccine therapy and biological&#xD;
      therapy in treating patients who have relapsed prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the optimal (in terms of antibody response) and safe dose range of&#xD;
           glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 in patients with&#xD;
           biochemically relapsed prostate cancer.&#xD;
&#xD;
        -  Assess post-immunization changes in prostate-specific antigen levels and other objective&#xD;
           parameters of disease in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of GPI-0100.&#xD;
&#xD;
      Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100&#xD;
      subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or&#xD;
      disease progression.&#xD;
&#xD;
      Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on&#xD;
      antibody response, is reached.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immune function</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a dose-escalation study of GPI-0100.&#xD;
Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.&#xD;
Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.&#xD;
Patients are followed every 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GPI-0100</intervention_name>
    <arm_group_label>vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MUC-2-Globo H-KLH conjugate vaccine</intervention_name>
    <arm_group_label>vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  Biochemically progressive disease after primary surgery or radiotherapy with or&#xD;
             without neoadjuvant androgen ablation&#xD;
&#xD;
               -  Greater than 50% increase in PSA level above baseline value of 1.0 ng/mL&#xD;
                  post-prostatectomy or 2.0 ng/mL post-radiotherapy, based on 3 successive&#xD;
                  determinations taken at 2-week intervals&#xD;
&#xD;
          -  Patients with prior intermittent hormonal therapy and non-castrate levels of&#xD;
             testosterone are eligible&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
          -  No radiographic evidence of metastasis&#xD;
&#xD;
          -  No active CNS or epidural tumor&#xD;
&#xD;
          -  No soft tissue and/or bone disease&#xD;
&#xD;
          -  No androgen-independence with no evidence of radiographic disease&#xD;
&#xD;
          -  May not be symptomatic or anticipated to develop symptoms within 6 months of study&#xD;
             entry&#xD;
&#xD;
          -  Concurrent registration to protocol MSKCC-90-040 required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL OR&#xD;
&#xD;
          -  SGOT less than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac disease (New York Heart Association class III or IV)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe debilitating pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No positive stool guaiac except hemorrhoids or history of documented radiation-induced&#xD;
             proctitis&#xD;
&#xD;
          -  No narcotic-dependent pain&#xD;
&#xD;
          -  No infection requiring antibiotics&#xD;
&#xD;
          -  No requirement for immunosuppressive therapy&#xD;
&#xD;
          -  No allergy to seafood&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since change in hormonal therapy (except to maintain castrate levels&#xD;
             of testosterone), including prednisone or dexamethasone&#xD;
&#xD;
          -  At least 8 weeks since prior suramin and/or documented plasma concentration&#xD;
&#xD;
          -  of suramin is less than 50 micrograms/mL (replacement hydrocortisone allowed)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to only measurable lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent surgery of only measurable lesion&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No other concurrent oncolytic agents&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Slovin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

